- Home
- HNVR vs INBX Comparison
HNVR vs INBX Comparison
Compare HNVR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- INBX
- Stock Information
- Founded
- HNVR 2008
- INBX 2010
- Country
- HNVR United States
- INBX United States
- Employees
- HNVR N/A
- INBX 161
- Industry
- HNVR Commercial Banks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- INBX Health Care
- Exchange
- HNVR Nasdaq
- INBX Nasdaq
- Market Cap
- HNVR 163.2M
- INBX 168.1M
- IPO Year
- HNVR 2022
- INBX 2020
- Fundamental
- Price
- HNVR $20.70
- INBX $11.47
- Analyst Decision
- HNVR Buy
- INBX Hold
- Analyst Count
- HNVR 1
- INBX 1
- Target Price
- HNVR $22.00
- INBX N/A
- AVG Volume (30 Days)
- HNVR 15.1K
- INBX 144.3K
- Earning Date
- HNVR 04-29-2025
- INBX 05-08-2025
- Dividend Yield
- HNVR 1.95%
- INBX 7.40%
- EPS Growth
- HNVR N/A
- INBX N/A
- EPS
- HNVR 1.66
- INBX 112.62
- Revenue
- HNVR $63,491,000.00
- INBX $200,000.00
- Revenue This Year
- HNVR N/A
- INBX N/A
- Revenue Next Year
- HNVR $15.80
- INBX N/A
- P/E Ratio
- HNVR $12.47
- INBX $0.10
- Revenue Growth
- HNVR 5.04
- INBX N/A
- 52 Week Low
- HNVR $13.62
- INBX $10.80
- 52 Week High
- HNVR $27.14
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- HNVR 46.68
- INBX 34.68
- Support Level
- HNVR $18.60
- INBX $10.81
- Resistance Level
- HNVR $21.05
- INBX $12.06
- Average True Range (ATR)
- HNVR 1.22
- INBX 1.00
- MACD
- HNVR 0.08
- INBX -0.19
- Stochastic Oscillator
- HNVR 50.00
- INBX 18.52
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.